You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 105 No. 8, August 1987 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha

K. Crawford and P. L. Kaufman

Twice daily topical application of 50 micrograms of prostaglandin F2 alpha tromethamine to cynomolgus monkey eyes produced significant ocular hypotension lasting at least six hours, with the intraocular pressure (IOP) falling between 35% and 50%, ie, to about 8 to 10 mm Hg, following the seventh dose. A single topical application of 1 mg of pilocarpine hydrochloride produced a much smaller IOP reduction and strong, probably maximal accommodation, both of which lasted at least eight hours. When prostaglandin F2 alpha-treated eyes were given pilocarpine before the seventh dose of prostaglandin F2 alpha, accommodation and IOP responded as in eyes receiving pilocarpine only. Atropine sulfate pretreatment of eyes receiving pilocarpine and prostaglandin F2 alpha completely prevented pilocarpine-induced accommodation and inhibition of ocular hypotension induced by prostaglandin F2 alpha. We hypothesize that (1) prostaglandin F2 alpha reduces IOP by increasing uveoscleral drainage of aqueous humor, and (2) pilocarpine pretreatment contracts the ciliary muscle, obliterating the intramuscular spaces and closing off the uveoscleral drainage pathway and thus physiologically blocking the effect.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review
Hodge et al.
Br. J. Ophthalmol. 2008;92:7-12.
ABSTRACT | FULL TEXT  

Acute Effects of PGF2{alpha} on MMP-2 Secretion from Human Ciliary Muscle Cells: A PKC- and ERK-Dependent Process
Husain et al.
IOVS 2005;46:1706-1713.
ABSTRACT | FULL TEXT  

Aqueous Humor Dynamics in Monkeys after Topical 8-Iso PGE2
Gabelt et al.
IOVS 2004;45:892-899.
ABSTRACT | FULL TEXT  

Morphological Changes in the Anterior Eye Segment after Long-Term Treatment with Different Receptor Selective Prostaglandin Agonists and a Prostamide
Richter et al.
IOVS 2003;44:4419-4426.
ABSTRACT | FULL TEXT  

An Aldose Reductase with 20alpha -Hydroxysteroid Dehydrogenase Activity Is Most Likely the Enzyme Responsible for the Production of Prostaglandin F2alpha in the Bovine Endometrium
Madore et al.
J. Biol. Chem. 2003;278:11205-11212.
ABSTRACT | FULL TEXT  

Alterations in Arachidonic Acid Release and Phospholipase C-{beta}1 Expression in Glaucomatous Human Ciliary Muscle Cells
Husain et al.
IOVS 2002;43:1127-1134.
ABSTRACT | FULL TEXT  

From PGF2{{alpha}}-Isopropyl Ester to Latanoprost: A Review of the Development of Xalatan The Proctor Lecture
Stjernschantz
IOVS 2001;42:1134-1145.
FULL TEXT  

Responses of Intraocular Pressure and the Pupil of Feline Eyes to Prostaglandin EP1 and FP Receptor Agonists
Bhattacherjee et al.
IOVS 1999;40:3047-3053.
ABSTRACT | FULL TEXT  

Flow after Prostaglandin E1 Is Mediated by Receptor-Coupled Adenylyl Cyclase in Human Anterior Segments
Dijkstra et al.
IOVS 1999;40:2622-2626.
ABSTRACT | FULL TEXT  

Medical Management of Glaucoma
Alward
NEJM 1998;339:1298-1307.
FULL TEXT  

Functional Characterization of the Ocular Prostaglandin F2alpha (PGF2alpha ) Receptor. ACTIVATION BY THE ISOPROSTANE, 12-iso-PGF2alpha
Kunapuli et al.
J. Biol. Chem. 1997;272:27147-27154.
ABSTRACT | FULL TEXT  

Effects on IOP restoration and blood-aqueous barrier after long term treatment with latanoprost in open angle glaucoma and ocular hypertension
Linden et al.
Br. J. Ophthalmol. 1997;81:370-372.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.